These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 15903242)

  • 1. Effects of elevated pCO2 and osmolality on growth of CHO cells and production of antibody-fusion protein B1: a case study.
    Zhu MM; Goyal A; Rank DL; Gupta SK; Vanden Boom T; Lee SS
    Biotechnol Prog; 2005; 21(1):70-7. PubMed ID: 15903242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selected amino acids protect hybridoma and CHO cells from elevated carbon dioxide and osmolality.
    deZengotita VM; Abston LR; Schmelzer AE; Shaw S; Miller WM
    Biotechnol Bioeng; 2002 Jun; 78(7):741-52. PubMed ID: 12001166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperosmotic stress and elevated pCO2 alter monoclonal antibody charge distribution and monosaccharide content.
    Schmelzer AE; Miller WM
    Biotechnol Prog; 2002; 18(2):346-53. PubMed ID: 11934306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dependence on glucose limitation of the pCO2 influences on CHO cell growth, metabolism and IgG production.
    Takuma S; Hirashima C; Piret JM
    Biotechnol Bioeng; 2007 Aug; 97(6):1479-88. PubMed ID: 17318909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying inhibitory threshold values of repressing metabolites in CHO cell culture using multivariate analysis methods.
    Xing Z; Li Z; Chow V; Lee SS
    Biotechnol Prog; 2008; 24(3):675-83. PubMed ID: 18422365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel control scheme for inducing angiostatin-human IgG fusion protein production using recombinant CHO cells in a oscillating bioreactor.
    Wang IK; Hsieh SY; Chang KM; Wang YC; Chu A; Shaw SY; Ou JJ; Ho L
    J Biotechnol; 2006 Feb; 121(3):418-28. PubMed ID: 16162365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic approach for scale-down model development and characterization of commercial cell culture processes.
    Li F; Hashimura Y; Pendleton R; Harms J; Collins E; Lee B
    Biotechnol Prog; 2006; 22(3):696-703. PubMed ID: 16739951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosylation of CHO-derived recombinant tPA produced under elevated pCO2.
    Kimura R; Miller WM
    Biotechnol Prog; 1997; 13(3):311-7. PubMed ID: 9190082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular pH monitoring as a tool for the study of hybridoma cell behavior in batch and continuous bioreactor cultures.
    Cherlet M; Marc A
    Biotechnol Prog; 1998; 14(4):626-38. PubMed ID: 9694686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of elevated pCO(2) and/or osmolality on the growth and recombinant tPA production of CHO cells.
    Kimura R; Miller WM
    Biotechnol Bioeng; 1996 Oct; 52(1):152-60. PubMed ID: 18629861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of culture environment for improved polyethylenimine-mediated transient production of recombinant monoclonal antibodies by CHO cells.
    Galbraith DJ; Tait AS; Racher AJ; Birch JR; James DC
    Biotechnol Prog; 2006; 22(3):753-62. PubMed ID: 16739959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreasing lactate level and increasing antibody production in Chinese Hamster Ovary cells (CHO) by reducing the expression of lactate dehydrogenase and pyruvate dehydrogenase kinases.
    Zhou M; Crawford Y; Ng D; Tung J; Pynn AF; Meier A; Yuk IH; Vijayasankaran N; Leach K; Joly J; Snedecor B; Shen A
    J Biotechnol; 2011 Apr; 153(1-2):27-34. PubMed ID: 21392546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioprocess development for the production of a recombinant MUC1 fusion protein expressed by CHO-K1 cells in protein-free medium.
    Link T; Bäckström M; Graham R; Essers R; Zörner K; Gätgens J; Burchell J; Taylor-Papadimitriou J; Hansson GC; Noll T
    J Biotechnol; 2004 May; 110(1):51-62. PubMed ID: 15099905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced interferon-beta production by CHO cells through elevated osmolality and reduced culture temperature.
    Han YK; Koo TY; Lee GM
    Biotechnol Prog; 2009; 25(5):1440-7. PubMed ID: 19572287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Process parameter shifting: Part II. Biphasic cultivation-A tool for enhancing the volumetric productivity of batch processes using Epo-Fc expressing CHO cells.
    Trummer E; Fauland K; Seidinger S; Schriebl K; Lattenmayer C; Kunert R; Vorauer-Uhl K; Weik R; Borth N; Katinger H; Müller D
    Biotechnol Bioeng; 2006 Aug; 94(6):1045-52. PubMed ID: 16736532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scale-up analysis for a CHO cell culture process in large-scale bioreactors.
    Xing Z; Kenty BM; Li ZJ; Lee SS
    Biotechnol Bioeng; 2009 Jul; 103(4):733-46. PubMed ID: 19280669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells.
    Borys MC; Dalal NG; Abu-Absi NR; Khattak SF; Jing Y; Xing Z; Li ZJ
    Biotechnol Bioeng; 2010 Apr; 105(6):1048-57. PubMed ID: 20039310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A predictive high-throughput scale-down model of monoclonal antibody production in CHO cells.
    Legmann R; Schreyer HB; Combs RG; McCormick EL; Russo AP; Rodgers ST
    Biotechnol Bioeng; 2009 Dec; 104(6):1107-20. PubMed ID: 19623562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temperature reduction in cultures of hGM-CSF-expressing CHO cells: effect on productivity and product quality.
    Bollati-Fogolín M; Forno G; Nimtz M; Conradt HS; Etcheverrigaray M; Kratje R
    Biotechnol Prog; 2005; 21(1):17-21. PubMed ID: 15903236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors.
    Trummer E; Fauland K; Seidinger S; Schriebl K; Lattenmayer C; Kunert R; Vorauer-Uhl K; Weik R; Borth N; Katinger H; Müller D
    Biotechnol Bioeng; 2006 Aug; 94(6):1033-44. PubMed ID: 16736530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.